Research Associate II/ Senior Research Associate, Therapeutic Translation

Profluent is an AI-first protein design company. Founded in 2022, we develop deep generative models to design and validate novel, functional proteins to revolutionize biomedicine. Based in Emeryville, CA, we are backed by leading investors including Spark Capital, Insight Partners, Air Street Capital, AIX Ventures, and Convergent Ventures.

Profluent is currently seeking a creative, passionate, and detail-oriented individual to join our team. The candidate will develop, automate and execute high throughput cell-based and in vitro gene editing assays. This individual will be critical in Profluent’s quest to develop powerful and novel gene editing technology to address major unmet needs in therapeutics and beyond.

This is an excellent opportunity to shape the future of AI-driven protein design and to work cross-functionally with a diverse team of experts across machine learning, protein engineering, cell biology, and gene editing.

Responsibilities

  • Develop, execute and automate cell-based and in vitro gene editing assays, using a variety of assay readouts, including flow cytometry, NGS and fluorescence
  • Perform mammalian cell culture and transfection for arrayed and pooled screening
  • Design and execute low throughput and high throughput plasmid cloning campaigns for construction of protein libraries
  • Precisely track and document experimental samples, assay data, and results
  • Analyze experimental data and interpret results
  • Present experimental results to colleagues in team and cross-team meetings
  • Contribute to lab maintenance and adhere to EHS standards

Qualifications

  • BS or MS in Molecular Biology, Biochemistry, Cell Biology, or a related field 
  • 2-6 years of biotechnology industry research experience or equivalent academic experience
  • Extensive, hands-on experience with mammalian cell culture and molecular biology
  • Excellent communication skills and the ability to work collaboratively across interdisciplinary teams
  • Strong organizational skills to accurately track laboratory samples and experimental data

Preferences (but not required)

  • Experience with CRISPR and/or mammalian cell-based gene editing assays
  • Experience with high throughput screening workflows
  • Experience with process development for automation workflows
  • Experience processing and analyzing large experimental datasets

Actual salary will be determined based on relevant skills, qualifications, experience, training, and market data. Benefits package may vary depending on company policies and eligibility criteria.

Hiring Salary Range
$83,600$127,000 USD

What we offer at Profluent

  • A high-growth opportunity with meaningful impact
  • Competitive compensation package
  • Health insurance (health/dental/vision)
  • Generous paid time off (PTO) policy
  • Commitment to physical and mental well-being
  • More benefits and perks to be added!

Profluent Bio, Inc is an equal opportunity employer promoting diversity and inclusion in the workspace. We do not discriminate on the basis of race, color, religion, marital status, age, national origin, ancestry, physical or mental disability, medical conditions, veteran status, sexual orientation, gender (including gender identity and gender expression), sex (which includes pregnancy, childbirth, and breastfeeding), genetic information, taking or requesting statutorily protected leave, or any other basis protected by law.

Legal authorization to work in the United States is required. In compliance with federal law, all persons hired will be required to verify identity and eligibility to work in the United States and to complete the required employment eligibility verification form upon hire.

Apply for this job
logo Profulent Biotechnology Full-time 💰 83.6K - 127K / annual On-site 📍 Emeryville, California, United States Apply Now
Your subscription could not be saved. Please try again.
Your subscription has been successful.

Newsletter

Subscribe and stay updated.

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Join our newsletter